Form 4: Alan Mateo Receives 10x Genomics RSU Grant

Director Alan Mateo was granted 8,829 restricted stock units by 10x Genomics, Inc. as part of his compensation.

Summary

• Director Alan Mateo acquired 8,829 restricted stock units (RSUs) of 10x Genomics, Inc. (TXG) Class A Common Stock.
• The transaction occurred on June 4, 2026.
• The RSUs represent a contingent right to receive one share of Class A Common Stock per unit upon vesting.
• Vesting occurs in quarterly installments starting from May 21, 2026, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding director compensation, which has no material impact on the company's financial position.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard equity grant for a director.

Risks

• Vesting is subject to the director continuing as a service provider to the company.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the director's equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology and life sciences sector to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation packages for publicly traded life sciences companies.
• The vesting schedule of quarterly installments is a common retention mechanism used by firms like Illumina or Pacific Biosciences.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• Quarterly vesting of the granted RSUs.

Key Dates

Keywords

10x Genomics, TXG, Director Compensation, Restricted Stock Units, Insider Transaction, SEC Form 4